Rhythm Stock Plunges 10%, Wiping Out $655 Million, As It Commits $350 Million To LG Chem

Shares fell on the day Rhythm reported $92.13 million in quarterly revenue and agreed to a $350 million payment to cut a drug royalty.

Share
Rhythm Stock Plunges 10%, Wiping Out $655 Million, As It Commits $350 Million To LG Chem

Rhythm Pharmaceuticals, which sells and develops drugs for rare diseases in which hunger and weight are not regulated normally, fell 10.18% to $83.93 in Tuesday trading, as of 10:17 a.m. ET, erasing $655 million in market value. The drop came the day it reported third-quarter revenue of $92.13 million and agreed to pay LG Chem $350 million to cut the royalty on its obesity drug candidate bivamelagon.

A $350 million royalty buydown

Under an amended license, Rhythm will pay LG Chem $350 million in four installments through September 2029. In exchange it owes a 1% royalty on its MC4R portfolio, replacing a variable royalty in the low-to-mid single digits.

To support the deal and its commercial push, the company secured a five-year term loan facility of up to $750 million, according to its release.

The company reported a loss of $0.61 per share for the quarter. The stock was on pace for its biggest one-day drop in at least 275 trading sessions, since Sept. 30, 2025.

A stock already down for the year

Rhythm's main product, Imcivree (setmelanotide), is approved in the United States, the European Union, the United Kingdom and Canada for severe obesity caused by certain genetic conditions. Bivamelagon and RM-718 are earlier-stage candidates.

Shares were down about 13% year to date at Monday's close, against a gain of about 10% for the S&P 500, and sat 21% below their highest close of the past year, set on Dec. 11, 2025. That came even as Imcivree kept growing: second-quarter revenue rose 46.9% from a year earlier, though the company still posted a net loss of $49.3 million.

In acquired hypothalamic obesity, Imcivree had 700 patient start forms from more than 500 prescribers as of Sept. 30, the company said, roughly six months after FDA approval for that use.

Rhythm plans to start pivotal trials of bivamelagon in acquired hypothalamic obesity and Prader-Willi syndrome.

Sources

More on Rhythm Pharmaceuticals

All Rhythm Pharmaceuticals (RYTM) coverage →